drugset / Trial / NCT07311863
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
Phase 0
Not yet recruiting
6 enrolled
Suzhou UgeneX Therapeutics Co., Ltd.
Eye & ENT Hospital of Fudan University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Timeline
- Start
- 2026-01
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UGX202 | Gene therapy (AAV / viral vector) | 4.2e+10 vg | Intravitreal |
| Subject | UGX202 | Gene therapy (AAV / viral vector) | 1.2e+11 vg | Intravitreal |